BRPI1014089A2 - anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples - Google Patents
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simplesInfo
- Publication number
- BRPI1014089A2 BRPI1014089A2 BRPI1014089A BRPI1014089A BRPI1014089A2 BR PI1014089 A2 BRPI1014089 A2 BR PI1014089A2 BR PI1014089 A BRPI1014089 A BR PI1014089A BR PI1014089 A BRPI1014089 A BR PI1014089A BR PI1014089 A2 BRPI1014089 A2 BR PI1014089A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- full length
- single chain
- fab fragments
- chain fab
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09004909 | 2009-04-02 | ||
PCT/EP2010/002004 WO2010112193A1 (en) | 2009-04-02 | 2010-03-30 | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1014089A2 true BRPI1014089A2 (pt) | 2016-04-19 |
Family
ID=40937376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1014089A BRPI1014089A2 (pt) | 2009-04-02 | 2010-03-30 | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
Country Status (19)
Country | Link |
---|---|
US (1) | US9382323B2 (pt) |
EP (1) | EP2414391B1 (pt) |
JP (1) | JP5501439B2 (pt) |
KR (1) | KR101431318B1 (pt) |
CN (1) | CN102369215B (pt) |
AR (1) | AR076018A1 (pt) |
AU (1) | AU2010230563A1 (pt) |
BR (1) | BRPI1014089A2 (pt) |
CA (1) | CA2756244A1 (pt) |
CL (1) | CL2011002380A1 (pt) |
HK (1) | HK1167669A1 (pt) |
IL (1) | IL214756A0 (pt) |
MX (1) | MX2011010159A (pt) |
PE (1) | PE20120591A1 (pt) |
RU (1) | RU2598248C2 (pt) |
SG (1) | SG175004A1 (pt) |
TW (1) | TW201040265A (pt) |
WO (1) | WO2010112193A1 (pt) |
ZA (1) | ZA201106666B (pt) |
Families Citing this family (274)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
CA2761233A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
GB201005064D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
EP2848940A1 (en) | 2010-07-19 | 2015-03-18 | F. Hoffmann-La Roche AG | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
MX2013000676A (es) | 2010-07-19 | 2013-02-27 | Hoffmann La Roche | Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anti-cancer. |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
JP5953303B2 (ja) | 2010-07-29 | 2016-07-20 | ゼンコア インコーポレイテッド | 改変された等電点を有する抗体 |
EP2600898A1 (en) | 2010-08-05 | 2013-06-12 | F.Hoffmann-La Roche Ag | Anti-mhc antibody anti-viral cytokine fusion protein |
RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
WO2012116926A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
MX342034B (es) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
IN2013MN01438A (pt) * | 2011-03-17 | 2015-06-12 | Univ Ramot | |
AU2012244816B2 (en) | 2011-04-20 | 2015-12-10 | Roche Glycart Ag | Method and constructs for the pH dependent passage of the blood-brain-barrier |
AR086924A1 (es) | 2011-06-15 | 2014-01-29 | Hoffmann La Roche | Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion |
MX354663B (es) | 2011-06-22 | 2018-03-14 | Hoffmann La Roche | Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase i. |
JP6159724B2 (ja) * | 2011-08-23 | 2017-07-05 | ロシュ グリクアート アーゲー | T細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法 |
WO2013041462A1 (en) | 2011-09-23 | 2013-03-28 | Roche Glycart Ag | Bispecific anti-egfr/anti igf-1r antibodies |
CN104080811B (zh) | 2011-11-04 | 2019-09-27 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
MX349003B (es) | 2011-12-19 | 2017-07-06 | Hoffmann La Roche | Metodo para la deteccion del asociado de union libre de un aglutinante multiespecifico. |
KR20140107295A (ko) | 2011-12-22 | 2014-09-04 | 에프. 호프만-라 로슈 아게 | 진핵 세포용 전장 항체 표시 시스템 및 그것의 용도 |
SG11201403443WA (en) | 2011-12-22 | 2014-07-30 | Hoffmann La Roche | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
KR102184059B1 (ko) | 2011-12-22 | 2020-11-30 | 에프. 호프만-라 로슈 아게 | 발현 벡터 구성, 신규한 생산 세포 생성 방법 및 폴리펩티드의 재조합 생산을 위한 그의 용도 |
CN106443016B (zh) | 2012-02-01 | 2019-08-13 | 弗·哈夫曼-拉罗切有限公司 | 用于检测多特异性结合物的结合搭档的方法 |
CN104379601B (zh) | 2012-02-03 | 2021-04-09 | 霍夫曼-拉罗奇有限公司 | 双特异性抗体分子和抗原-转染的t-细胞以及它们在医药中的用途 |
CA2861124A1 (en) * | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
JP6152120B2 (ja) | 2012-02-15 | 2017-06-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Fc受容体に基づくアフィニティークロマトグラフィー |
PE20142422A1 (es) | 2012-04-05 | 2015-01-21 | Hoffmann La Roche | Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos |
CN104583239B (zh) | 2012-05-10 | 2018-09-18 | 生物蛋白有限公司 | 多特异单克隆抗体 |
US9499634B2 (en) | 2012-06-25 | 2016-11-22 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
MX354862B (es) | 2012-06-27 | 2018-03-23 | Hoffmann La Roche | Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes. |
CN104411718B (zh) | 2012-06-27 | 2018-04-24 | 弗·哈夫曼-拉罗切有限公司 | 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途 |
BR112014030844A2 (pt) | 2012-07-04 | 2019-10-15 | Hoffmann La Roche | anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo |
JP6148729B2 (ja) | 2012-07-04 | 2017-06-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 共有結合している抗原−抗体結合体 |
CN104394886B (zh) | 2012-07-04 | 2017-05-24 | 弗·哈夫曼-拉罗切有限公司 | 抗茶碱抗体及使用方法 |
ES2627482T3 (es) | 2012-07-13 | 2017-07-28 | F. Hoffmann-La Roche Ag | Procedimiento para la detección de una proteína de unión multiespecífica |
EP2890712B1 (en) * | 2012-08-29 | 2019-05-01 | F.Hoffmann-La Roche Ag | Blood brain barrier shuttle |
BR112015003938A2 (pt) | 2012-09-14 | 2018-09-04 | Hoffmann La Roche | métodos de produção de polipeptídeos, de produção de aglutinantes multiespecíficos, de seleção de aglutinantes multiespecíficos, de seleção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação farmcêutica e uso de anticorpo biespecífico |
BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
EA201500502A1 (ru) | 2012-11-08 | 2015-10-30 | Ф.Хоффманн-Ля Рош Аг | Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3 |
CA2893562C (en) | 2012-11-28 | 2023-09-12 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
MX2015010350A (es) | 2013-02-26 | 2015-10-29 | Roche Glycart Ag | Moleculas de union a antigeno biespecificas que activan la celula t. |
EA201891502A1 (ru) | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
PL2992012T3 (pl) | 2013-04-29 | 2019-12-31 | F. Hoffmann-La Roche Ag | Zmodyfikowane ludzkie przeciwciała wiążące FcRn i sposoby ich zastosowania |
SG10201810481UA (en) | 2013-04-29 | 2018-12-28 | Hoffmann La Roche | Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases |
RU2019108429A (ru) | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения |
WO2014182970A1 (en) | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
WO2015025054A1 (en) | 2013-08-22 | 2015-02-26 | Medizinische Universität Wien | Dye-specific antibodies for prestained molecular weight markers and methods producing the same |
CN105612182B (zh) | 2013-10-11 | 2019-12-10 | 豪夫迈·罗氏有限公司 | 多特异性结构域交换共有可变轻链抗体 |
SG10202007189VA (en) | 2013-11-21 | 2020-09-29 | Hoffmann La Roche | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE |
CN105980409B (zh) | 2013-11-27 | 2023-07-18 | 酵活生物制药有限公司 | 靶向her2的双特异性抗原结合构建体 |
WO2015091656A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE |
AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
JP6602304B2 (ja) | 2014-01-03 | 2019-11-06 | エフ.ホフマン−ラ ロシュ アーゲー | 共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途 |
EP3089996B1 (en) | 2014-01-03 | 2021-07-28 | F. Hoffmann-La Roche AG | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
MX2016008191A (es) | 2014-01-03 | 2017-11-16 | Hoffmann La Roche | Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente. |
CN111057151B (zh) | 2014-01-06 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 单价血脑屏障穿梭模块 |
MX2016008782A (es) | 2014-01-15 | 2016-09-08 | Hoffmann La Roche | Variantes de region fc con union mejorada de la proteina a. |
CA2931986A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
JP6640181B2 (ja) * | 2014-03-21 | 2020-02-05 | エックス−ボディ インコーポレイテッド | 二重特異性抗原結合ポリペプチド |
AU2015237184B2 (en) | 2014-03-28 | 2020-11-26 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
JP6666262B2 (ja) | 2014-04-02 | 2020-03-13 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性抗体の軽鎖誤対合を検出するための方法 |
EP3129051A1 (en) | 2014-04-08 | 2017-02-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
KR102493430B1 (ko) | 2014-05-28 | 2023-01-31 | 자임워크스 비씨 인코포레이티드 | 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도 |
WO2015184626A1 (en) | 2014-06-05 | 2015-12-10 | Wuhan Yzy Biopharma Co., Ltd | Preparation and selection of cells for producing bispecific antibodies |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
MX2016015280A (es) | 2014-06-26 | 2017-03-03 | Hoffmann La Roche | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. |
AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
JP6702893B2 (ja) * | 2014-06-27 | 2020-06-03 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的抗原結合タンパク質 |
TW201623329A (zh) | 2014-06-30 | 2016-07-01 | 亞佛瑞司股份有限公司 | 針對骨調素截斷變異體的疫苗及單株抗體暨其用途 |
ES2785551T3 (es) | 2014-06-30 | 2020-10-07 | Glykos Finland Oy | Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos |
JP6876601B2 (ja) | 2014-07-10 | 2021-05-26 | アフィリス・アクチェンゲゼルシャフトAffiris Ag | ハンチントン病の予防および/または処置における使用のための物質および方法 |
KR102317315B1 (ko) | 2014-08-04 | 2021-10-27 | 에프. 호프만-라 로슈 아게 | 이중특이적 t 세포 활성화 항원 결합 분자 |
CN107074966A (zh) | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体 |
JP6707090B2 (ja) | 2014-11-06 | 2020-06-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | FcRn結合が変更されたFc領域変種および使用方法 |
ES2835823T3 (es) | 2014-11-20 | 2021-06-23 | Hoffmann La Roche | Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
MY184268A (en) | 2014-11-26 | 2021-03-30 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
US20170269092A1 (en) | 2014-12-02 | 2017-09-21 | Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
KR20170094787A (ko) | 2014-12-18 | 2017-08-21 | 에프. 호프만-라 로슈 아게 | Cdc 유발 항체를 측정하기 위한 검정 및 방법 |
NZ732628A (en) | 2014-12-22 | 2019-01-25 | Systimmune Inc | Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
KR101798747B1 (ko) | 2015-02-02 | 2017-11-17 | 성균관대학교산학협력단 | 코일드 코일 단백질 및 그의 용도 |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
PL3313877T3 (pl) | 2015-06-24 | 2020-11-02 | F. Hoffmann-La Roche Ag | Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania |
IL302486A (en) | 2015-06-24 | 2023-06-01 | Hoffmann La Roche | Antibodies against the transnephrine receptor with adapted affinity |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
CN108137699B (zh) | 2015-10-02 | 2022-05-27 | 豪夫迈·罗氏有限公司 | 对pd1和tim3特异性的双特异性抗体 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
MA43018B1 (fr) | 2015-10-02 | 2021-11-30 | Hoffmann La Roche | Anticorps anti-pd1 et procédés d'utilisation |
WO2017055399A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Cellular based fret assay for the determination of simultaneous binding |
TWI747843B (zh) | 2015-10-02 | 2021-12-01 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
KR20180073561A (ko) | 2015-10-02 | 2018-07-02 | 에프. 호프만-라 로슈 아게 | 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자 |
RU2018116846A (ru) | 2015-10-08 | 2019-11-08 | Займворкс Инк. | Антигенсвязывающие полипептидные конструкции, содержащие легкие цепи каппа и лямбда, и их применения |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
KR20180069065A (ko) | 2015-10-29 | 2018-06-22 | 에프. 호프만-라 로슈 아게 | 항-변이체 fc-부위 항체 및 사용 방법 |
CN105542011A (zh) * | 2015-11-18 | 2016-05-04 | 北京嘉泰先科医药科技有限公司 | 双特异性或多特异性Ig JR结合蛋白 |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
CN108290954B (zh) | 2015-12-09 | 2022-07-26 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
CN108368179B (zh) | 2016-01-08 | 2022-08-23 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法 |
US11421028B2 (en) | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
AU2017238172A1 (en) | 2016-03-21 | 2018-09-13 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
SI3433280T1 (sl) | 2016-03-22 | 2023-07-31 | F. Hoffmann-La Roche Ag | S proteazo aktivirane bispecifične molekule celic T |
US11753438B2 (en) | 2016-05-11 | 2023-09-12 | Cytiva Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US10730908B2 (en) * | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
EP4257613A3 (en) | 2016-06-14 | 2023-12-13 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
MX2018015173A (es) | 2016-06-17 | 2019-07-04 | Genentech Inc | Purificacion de anticuerpos multiespecificos. |
JP7021127B2 (ja) | 2016-06-28 | 2022-02-16 | ゼンコア インコーポレイテッド | ソマトスタチン受容体2に結合するヘテロ二量体抗体 |
AU2017297603A1 (en) | 2016-07-14 | 2019-02-14 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP6976315B2 (ja) | 2016-09-19 | 2021-12-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 補体因子に基づくアフィニティークロマトグラフィー |
JP6785372B2 (ja) * | 2016-09-30 | 2020-11-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性分子の機能分析のためのsprに基づく二重結合アッセイ |
JP7022123B2 (ja) | 2016-09-30 | 2022-02-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Cd3に対する二重特異性抗体 |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
WO2018071919A1 (en) | 2016-10-14 | 2018-04-19 | Xencor, Inc. | IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS |
WO2018075564A1 (en) * | 2016-10-17 | 2018-04-26 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
CR20190297A (es) | 2016-11-23 | 2019-11-01 | Bioverativ Therapeutics Inc | Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x |
AU2017381656B2 (en) | 2016-12-21 | 2020-07-02 | F. Hoffmann-La Roche Ag | Re-use of enzymes in in vitro glycoengineering of antibodies |
AU2017384276B9 (en) | 2016-12-21 | 2020-11-26 | F. Hoffmann-La Roche Ag | In vitro glycoengineering of antibodies |
EP3559249A1 (en) | 2016-12-21 | 2019-10-30 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of antibodies |
WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
DK3606946T3 (da) | 2017-04-03 | 2022-10-24 | Hoffmann La Roche | Immunkonjugater af et anti-PD-1-antistof med et muteret IL-2 eller med IL-15 |
WO2018184966A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Antibodies binding to steap-1 |
SI3606954T1 (sl) | 2017-04-05 | 2022-10-28 | F. Hoffmann - La Roche Ag | Protitelesa proti LAG3 |
TWI747215B (zh) | 2017-04-05 | 2021-11-21 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
SG11201912864SA (en) * | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
EP3645122A1 (en) | 2017-06-30 | 2020-05-06 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
PT3661954T (pt) | 2017-08-03 | 2022-04-14 | Amgen Inc | Muteínas de interleuquina-21 e métodos de tratamento |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
CA3082383A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US20200300852A1 (en) | 2017-11-29 | 2020-09-24 | Hoffmann-La Roche Inc. | Target interference suppressed anti-drug antibody assay |
KR20200100098A (ko) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
BR112020011469A2 (pt) | 2017-12-21 | 2020-11-24 | F. Hoffmann-La Roche Ag | anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção |
CN117050184A (zh) | 2017-12-28 | 2023-11-14 | 南京传奇生物科技有限公司 | 针对tigit的单域抗体和其变体 |
JP7436365B2 (ja) | 2017-12-29 | 2024-02-21 | エフ. ホフマン-ラ ロシュ アーゲー | 抗vegf抗体及び使用の方法 |
CN111836832A (zh) * | 2018-01-08 | 2020-10-27 | 南京传奇生物科技有限公司 | 多特异性抗原结合蛋白及其使用方法 |
SG11202005605SA (en) | 2018-01-12 | 2020-07-29 | Amgen Inc | Anti-pd-1 antibodies and methods of treatment |
JP7366908B2 (ja) | 2018-01-15 | 2023-10-23 | ナンジン レジェンド バイオテック カンパニー,リミテッド | Pd-1に対する単一ドメイン抗体及びその変異体 |
WO2019149715A1 (en) | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Stabilized immunoglobulin domains |
JP2021511793A (ja) | 2018-01-31 | 2021-05-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Lag3に結合する抗原結合部位を含む二重特異性抗体 |
AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2019191552A1 (en) | 2018-03-29 | 2019-10-03 | Genentech, Inc. | Modulating lactogenic activity in mammalian cells |
WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
AR115052A1 (es) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
EP3781599A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
CN110551216B (zh) * | 2018-05-31 | 2022-11-18 | 信达生物制药(苏州)有限公司 | 多价抗ox40抗体及其用途 |
EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
EP3838289A4 (en) | 2018-07-25 | 2022-08-03 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-TIGIT ANTIBODIES AND USES THEREOF |
EP3608674A1 (en) | 2018-08-09 | 2020-02-12 | Regeneron Pharmaceuticals, Inc. | Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor |
MA53822A (fr) | 2018-10-03 | 2021-08-11 | Xencor Inc | Protéines de fusion fc hétérodimères d'il -12 |
CR20210330A (es) | 2018-12-21 | 2021-07-20 | Hoffmann La Roche | ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325) |
EP3902560A1 (en) | 2018-12-28 | 2021-11-03 | F. Hoffmann-La Roche AG | A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response |
JP7241888B2 (ja) | 2018-12-30 | 2023-03-17 | エフ. ホフマン-ラ ロシュ アーゲー | pH勾配SPRに基づく結合アッセイ |
EP3927747A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
CN114127112A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 |
GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
GB2598218A (en) | 2019-02-21 | 2022-02-23 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
JP2022521750A (ja) | 2019-02-21 | 2022-04-12 | マレンゴ・セラピューティクス,インコーポレーテッド | カルレティキュリンに結合する多機能性分子およびその使用 |
CN114173875A (zh) | 2019-03-01 | 2022-03-11 | Xencor股份有限公司 | 结合enpp3和cd3的异二聚抗体 |
JP7412440B2 (ja) | 2019-03-29 | 2024-01-12 | エフ. ホフマン-ラ ロシュ アーゲー | アビド結合多重特異性抗体を作製する方法 |
CN113646622A (zh) | 2019-03-29 | 2021-11-12 | 豪夫迈·罗氏有限公司 | 用于多价分子的功能分析的基于spr的结合测定 |
WO2020229378A1 (en) | 2019-05-13 | 2020-11-19 | F. Hoffmann-La Roche Ag | Interference-suppressed pharmacokinetic immunoassay |
AU2020297940A1 (en) | 2019-06-19 | 2021-12-16 | F. Hoffmann-La Roche Ag | Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
CA3140287A1 (en) | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
MX2021015538A (es) | 2019-06-19 | 2022-02-10 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. |
EP3986928A1 (en) | 2019-06-19 | 2022-04-27 | F. Hoffmann-La Roche AG | Method for the generation of a protein expressing cell by targeted integration using cre mrna |
EP3986924A1 (en) | 2019-06-19 | 2022-04-27 | F. Hoffmann-La Roche AG | Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
KR20220016957A (ko) | 2019-06-26 | 2022-02-10 | 에프. 호프만-라 로슈 아게 | Sirt-1 유전자 녹아웃을 갖는 포유류 세포주 |
AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
JP2022543551A (ja) | 2019-07-31 | 2022-10-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Gprc5dに結合する抗体 |
KR20220028035A (ko) | 2019-07-31 | 2022-03-08 | 에프. 호프만-라 로슈 아게 | Gprc5d에 결합하는 항체 |
MX2022001682A (es) * | 2019-08-08 | 2022-05-13 | Regeneron Pharma | Nuevos formatos de moleculas de union a antigenos. |
CN112390882A (zh) * | 2019-08-19 | 2021-02-23 | 杨洋 | 靶向cd3和cd20的双特异性抗体及其应用 |
US20220411508A1 (en) * | 2019-09-09 | 2022-12-29 | The Regents Of The University Of California | Compositions and methods for making and using multispecific antibodies |
TW202126698A (zh) | 2019-09-18 | 2021-07-16 | 美商建南德克公司 | 抗klk7抗體、抗klk5抗體、多重特異性抗klk5/klk7抗體、及使用方法 |
CN114641270A (zh) | 2019-11-15 | 2022-06-17 | 豪夫迈·罗氏有限公司 | 防止水性蛋白质溶液中可见颗粒的形成 |
PE20221282A1 (es) | 2019-12-18 | 2022-09-05 | Hoffmann La Roche | Anticuerpos que se unen a hla-a2/mage-a4 |
IL293310A (en) | 2019-12-18 | 2022-07-01 | Hoffmann La Roche | Bispecific anti-ccl2 antibodies |
CR20220334A (es) | 2019-12-23 | 2022-08-26 | Genentech Inc | Anticuerpos específicos de apolipoproteína l1 y métodos de uso |
EP4085251A1 (en) | 2020-01-02 | 2022-11-09 | F. Hoffmann-La Roche AG | Method for determining the amount of a therapeutic antibody in the brain |
EP4084821A2 (en) | 2020-01-03 | 2022-11-09 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
JP2023510382A (ja) | 2020-01-15 | 2023-03-13 | エフ. ホフマン-ラ ロシュ アーゲー | 組換えタンパク質製造プロセスから不純物を減少させる方法 |
WO2021195464A2 (en) | 2020-03-26 | 2021-09-30 | Genentech, Inc. | Modified mammalian cells |
CN115843312A (zh) | 2020-04-24 | 2023-03-24 | 马伦戈治疗公司 | 结合至t细胞相关癌细胞的多功能性分子及其用途 |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
JP2023520249A (ja) | 2020-05-15 | 2023-05-16 | エフ. ホフマン-ラ ロシュ アーゲー | 非経口タンパク質溶液中の可視粒子形成の防止方法 |
JP2023525898A (ja) | 2020-05-19 | 2023-06-19 | エフ. ホフマン-ラ ロシュ アーゲー | 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用 |
JP2023527918A (ja) | 2020-06-08 | 2023-06-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗hbv抗体及び使用方法 |
MX2022015899A (es) | 2020-06-16 | 2023-01-24 | Hoffmann La Roche | Metodo para determinar antigeno libre de un anticuerpo en una muestra. |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
CN115698084A (zh) | 2020-06-19 | 2023-02-03 | 豪夫迈·罗氏有限公司 | 与cd3结合的抗体 |
AU2021291011A1 (en) | 2020-06-19 | 2023-01-05 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 and CD19 |
AU2021291005A1 (en) | 2020-06-19 | 2023-01-05 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 and FolR1 |
EP4172192A1 (en) | 2020-06-24 | 2023-05-03 | Genentech, Inc. | Apoptosis resistant cell lines |
CN116133689A (zh) | 2020-07-07 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 作为治疗性蛋白质制剂的稳定剂的替代表面活性剂 |
AU2021308653A1 (en) | 2020-07-17 | 2023-02-16 | Genentech, Inc. | Anti-Notch2 antibodies and methods of use |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
KR20230074144A (ko) | 2020-08-26 | 2023-05-26 | 마렝고 테라퓨틱스, 인크. | NKp30에 결합하는 항체 분자 및 이의 용도 |
AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
AU2021333779A1 (en) | 2020-08-26 | 2023-04-13 | Marengo Therapeutics, Inc. | Methods of detecting TRBC1 or TRBC2 |
TW202227625A (zh) | 2020-08-28 | 2022-07-16 | 美商建南德克公司 | 宿主細胞蛋白質之CRISPR/Cas9多重剔除 |
EP4214244A1 (en) | 2020-09-21 | 2023-07-26 | Genentech, Inc. | Purification of multispecific antibodies |
MX2023003328A (es) | 2020-09-24 | 2023-03-27 | Hoffmann La Roche | Lineas de celulas de mamifero con desactivacion genica. |
TW202233671A (zh) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Peg結合抗mertk抗體及其使用方法 |
JP2023548595A (ja) * | 2020-11-10 | 2023-11-17 | アムジエン・インコーポレーテツド | 多重特異性抗原結合ドメインの新規のリンカー |
KR20220082775A (ko) | 2020-12-10 | 2022-06-17 | 주식회사 유틸렉스 | 항-pd-1 항체 및 이의 용도 |
JP7326584B2 (ja) | 2020-12-17 | 2023-08-15 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗hla-g抗体及びその使用 |
JP2024501662A (ja) | 2020-12-22 | 2024-01-15 | エフ. ホフマン-ラ ロシュ アーゲー | Xbp1を標的とするオリゴヌクレオチド |
CA3203257A1 (en) | 2020-12-23 | 2022-06-30 | Li Li | Anti-b7-h3 antibody and uses thereof |
CN114716548A (zh) | 2021-01-05 | 2022-07-08 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
JP2024509695A (ja) | 2021-02-03 | 2024-03-05 | ジェネンテック, インコーポレイテッド | 多重特異性結合タンパク質分解プラットフォームおよび使用方法 |
CN116888473A (zh) | 2021-02-18 | 2023-10-13 | 豪夫迈·罗氏有限公司 | 用于解析复杂、多步骤抗体相互作用的方法 |
CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
JP2024512377A (ja) | 2021-03-12 | 2024-03-19 | ジェネンテック, インコーポレイテッド | 抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法 |
GB2623199A (en) | 2021-04-08 | 2024-04-10 | Marengo Therapeutics Inc | Multifunctional molecules binding to TCR and uses thereof |
WO2022214565A1 (en) | 2021-04-09 | 2022-10-13 | F. Hoffmann-La Roche Ag | Process for selecting cell clones expressing a heterologous polypeptide |
EP4326855A1 (en) | 2021-04-19 | 2024-02-28 | Genentech, Inc. | Modified mammalian cells |
KR20240010469A (ko) | 2021-05-21 | 2024-01-23 | 제넨테크, 인크. | 관심 재조합 생성물의 생성을 위한 변형된 세포 |
CN113278071B (zh) | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
CN117500829A (zh) | 2021-06-18 | 2024-02-02 | 豪夫迈·罗氏有限公司 | 双特异性抗ccl2抗体 |
KR20240032930A (ko) | 2021-07-13 | 2024-03-12 | 제넨테크, 인크. | 사이토카인 방출 증후군을 예측하기 위한 다변량 모델 |
WO2023001884A1 (en) | 2021-07-22 | 2023-01-26 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
CN113683694B (zh) | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | 一种抗人tslp单克隆抗体及其应用 |
CN113603775B (zh) | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
WO2023094282A1 (en) | 2021-11-25 | 2023-06-01 | F. Hoffmann-La Roche Ag | Quantification of low amounts of antibody sideproducts |
AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
WO2023117325A1 (en) | 2021-12-21 | 2023-06-29 | F. Hoffmann-La Roche Ag | Method for the determination of hydrolytic activity |
WO2023129974A1 (en) | 2021-12-29 | 2023-07-06 | Bristol-Myers Squibb Company | Generation of landing pad cell lines |
TW202340251A (zh) | 2022-01-19 | 2023-10-16 | 美商建南德克公司 | 抗notch2抗體及結合物及其使用方法 |
WO2023161457A1 (en) | 2022-02-27 | 2023-08-31 | Evobright Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
WO2023175171A1 (en) | 2022-03-18 | 2023-09-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Bk polyomavirus antibodies and uses thereof |
WO2023202967A1 (en) | 2022-04-19 | 2023-10-26 | F. Hoffmann-La Roche Ag | Improved production cells |
WO2023232961A1 (en) | 2022-06-03 | 2023-12-07 | F. Hoffmann-La Roche Ag | Improved production cells |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
Family Cites Families (246)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
SE8505922D0 (sv) | 1985-12-13 | 1985-12-13 | Kabigen Ab | Construction of an igg binding protein to facilitate downstream processing using protein engineering |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
DE68918323T2 (de) | 1988-04-01 | 1995-05-18 | Carter Wallace | Spezifische Spaltung von Peptidbindungen durch organische tertiäre Phosphine mit nukleophilen Seitenketten. |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
CA2046909A1 (en) | 1989-03-21 | 1990-09-22 | Mark D. Howell | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ES2112838T5 (es) | 1989-07-19 | 2004-09-01 | Connetics Corporation | Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas. |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
PT95809A (pt) | 1989-11-07 | 1991-09-13 | Bristol Myers Squibb Co | Processo para a preparacao de imunoglobulinas oligomericas, nomeadamente anticorpos monoclonais oligomericos |
JPH06500780A (ja) | 1990-08-31 | 1994-01-27 | ブリストル―マイアーズ スクイブ カンパニー | ホモ接合免疫グロブリン |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US6511663B1 (en) | 1991-06-11 | 2003-01-28 | Celltech R&D Limited | Tri- and tetra-valent monospecific antigen-binding proteins |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
CA2071137A1 (en) | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
ES2173873T5 (es) | 1992-10-28 | 2007-03-01 | Genentech, Inc. | Utilizacion de anticuerpos anti-vegf para el tratamiento del cancer. |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5532142A (en) | 1993-02-12 | 1996-07-02 | Board Of Regents, The University Of Texas System | Method of isolation and purification of fusion polypeptides |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
UA40577C2 (uk) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5824483A (en) | 1994-05-18 | 1998-10-20 | Pence Inc. | Conformationally-restricted combinatiorial library composition and method |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
GB9504344D0 (en) | 1995-03-03 | 1995-04-19 | Unilever Plc | Antibody fragment production |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
US6136564A (en) | 1995-11-16 | 2000-10-24 | Roche Diagnostics Gmbh | Process for the production of peptides by way of streptavidin fusion proteins |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
EP0894135B1 (en) | 1996-04-04 | 2004-08-11 | Unilever Plc | Multivalent and multispecific antigen-binding protein |
WO1997038123A1 (en) | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
US5755121A (en) | 1996-07-23 | 1998-05-26 | Master Lock Company | Lock body having opposing identical molded plastic sections |
ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
CN104231078A (zh) | 1997-04-07 | 2014-12-24 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
CA2297692A1 (en) | 1997-08-18 | 1999-02-25 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
AU2719099A (en) | 1998-01-23 | 1999-08-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Multipurpose antibody derivatives |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
DE69942148D1 (de) | 1998-06-22 | 2010-04-29 | Immunomedics Inc | Gebrauch von bispezifischen antikörpern in diagnose und therapie |
US7138103B2 (en) | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
DE69934425T2 (de) | 1998-10-23 | 2007-09-27 | Amgen Inc., Thousand Oaks | Thrombopoietin substitute |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
WO2000035956A1 (fr) | 1998-12-16 | 2000-06-22 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps monoclonal anti-vegf humain |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
US6872806B1 (en) | 1999-06-25 | 2005-03-29 | The Governors Of The University Of Alberta | Polypeptide compositions formed using a coiled-coil template and methods of use |
PL358215A1 (en) | 2000-03-24 | 2004-08-09 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
WO2001090192A2 (en) | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
KR100919593B1 (ko) * | 2000-06-29 | 2009-09-29 | 아보트 러보러터리즈 | 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물 |
CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6610472B1 (en) | 2000-10-31 | 2003-08-26 | Genetastix Corporation | Assembly and screening of highly complex and fully human antibody repertoire in yeast |
US8372954B2 (en) | 2000-12-22 | 2013-02-12 | National Research Council Of Canada | Phage display libraries of human VH fragments |
US20030027751A1 (en) | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
ES2387546T3 (es) | 2001-05-11 | 2012-09-25 | Amgen Inc. | Péptidos y moléculas relacionadas que se unen a TALL-1 |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
WO2003066660A2 (en) | 2002-02-05 | 2003-08-14 | Immunolex Therapeutics Aps | A PAIR OF ANTIBODY Fv FRAGMENTS STABILIZED BY COILEDCOIL PEPTIDES |
JP2006502091A (ja) * | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
WO2003093318A1 (en) | 2002-04-29 | 2003-11-13 | Genpat77 Pharmacogenetics Ag | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis |
US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
PT1517921E (pt) * | 2002-06-28 | 2006-09-29 | Domantis Ltd | Ligandos duplamente especificos com semi-vida no soro aumentada |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
BR0315123A (pt) | 2002-10-10 | 2005-08-16 | Merck Patent Gmbh | Composições farmacêuticas direcionadas a receptores erb-b1 |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
NZ603037A (en) | 2003-01-22 | 2014-05-30 | Roche Glycart Ag | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
US7575893B2 (en) | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
MXPA05008521A (es) | 2003-02-13 | 2005-10-20 | Pharmacia Corp | Anticuerpos a c-met para el tratamiento de canceres. |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
EP1639009B1 (en) | 2003-05-30 | 2013-02-27 | Merus B.V. | Fab library for the preparation of a mixture of antibodies |
KR20120104408A (ko) | 2003-05-30 | 2012-09-20 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
SI1639011T1 (sl) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
WO2005004809A2 (en) * | 2003-07-01 | 2005-01-20 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
AU2004261229A1 (en) | 2003-07-29 | 2005-02-10 | Eisai, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
JP2007503206A (ja) | 2003-08-22 | 2007-02-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法 |
AU2004273791A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
US20050064509A1 (en) | 2003-09-23 | 2005-03-24 | The Regents Of The University Of California | Use of templated self assembly to create novel multifunctional species |
CN1326881C (zh) | 2003-09-29 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种三价双特异性抗体,其制备方法及用途 |
HUE031632T2 (en) | 2003-11-05 | 2017-07-28 | Roche Glycart Ag | Antigen binding molecules with enhanced Fc receptor binding affinity and effector function |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
PL1718677T3 (pl) | 2003-12-19 | 2012-09-28 | Genentech Inc | Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze |
WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
JP2008510466A (ja) | 2004-08-19 | 2008-04-10 | ジェネンテック・インコーポレーテッド | エフェクター機能が変更しているポリペプチド変異体 |
JP4124365B2 (ja) * | 2004-08-24 | 2008-07-23 | 学校法人慶應義塾 | 電子回路 |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS |
AU2005319382B2 (en) | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
DK1871805T3 (da) | 2005-02-07 | 2019-12-02 | Roche Glycart Ag | Antigenbindende molekyler der binder egfr, vektorer der koder derfor, og anvendelser deraf |
CN101163501A (zh) | 2005-02-23 | 2008-04-16 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
WO2006089364A1 (en) | 2005-02-24 | 2006-08-31 | The University Of Queensland | Peptide networks |
JP2008531049A (ja) | 2005-02-28 | 2008-08-14 | セントカー・インコーポレーテツド | ヘテロ二量体タンパク質結合組成物 |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
JP5838021B2 (ja) | 2005-04-15 | 2015-12-24 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディとその使用 |
WO2006114700A2 (en) | 2005-04-26 | 2006-11-02 | Bioren, Inc. | Method of producing human igg antibodies with enhanced effector functions |
US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
MY169746A (en) | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
KR101460932B1 (ko) | 2005-08-26 | 2014-11-12 | 로슈 글리카트 아게 | 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자 |
WO2007044887A2 (en) * | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
TW200732350A (en) | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
ES2411505T3 (es) | 2005-12-15 | 2013-07-05 | Medimmune Limited | Combinación del antagonista de la angiopoyetina-2 y del antagonista de VEGF-A, y/o KDR, y/o Flt1 para el tratamiento del cáncer |
FR2894959B1 (fr) | 2005-12-15 | 2008-02-29 | Galderma Res & Dev | Derives biphenyliques agonistes selectifs du recepteur rar-gamma |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
CA2638794A1 (en) | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
NZ591252A (en) | 2006-03-17 | 2012-06-29 | Biogen Idec Inc | Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids |
CA2646965C (en) * | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
WO2008005828A2 (en) | 2006-06-30 | 2008-01-10 | Novo Nordisk A/S | PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS COMPRISING ANTIBODY MOLECULES SPECIFIC TO LAMININ-5 α3 CHAIN DOMAINS G1G2 AND USE THEREOF |
AR062223A1 (es) * | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
CN101205255A (zh) | 2006-12-14 | 2008-06-25 | 上海中信国健药业有限公司 | 抗cd20四价抗体、其制备方法和应用 |
CA2671734A1 (en) | 2006-12-19 | 2008-06-26 | Genentech, Inc. | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
US20080226635A1 (en) * | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN101037671B (zh) | 2007-02-14 | 2010-07-07 | 中国人民解放军军事医学科学院野战输血研究所 | 杂交瘤细胞株及其产生的抗人红细胞表面h抗原的单克隆抗体 |
MX2009008656A (es) | 2007-02-16 | 2009-11-10 | Merrimack Pharmaceuticals Inc | Anticuerpos contra erbb3 y usos de los mismos. |
US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
ES2628395T3 (es) | 2007-08-15 | 2017-08-02 | Bayer Pharma Aktiengesellschaft | Anticuerpo regulado por proteasa |
US20110245409A1 (en) | 2007-08-15 | 2011-10-06 | Hood David K | Polyvinylamide Polymers Containing Polymerizable Functionalities |
DE102007038753A1 (de) | 2007-08-16 | 2009-02-19 | Giesecke & Devrient Gmbh | Vorrichtung und Verfahren für die Kalibrierung eines Sensorsystems |
KR20100052545A (ko) | 2007-08-28 | 2010-05-19 | 바이오겐 아이덱 엠에이 인코포레이티드 | Igf―1r의 다중 에피토프에 결합하는 조성물 |
WO2009030780A2 (en) | 2007-09-07 | 2009-03-12 | Complix Nv | Non-natural proteinaceous scaffold made of three non-covalently associated peptides |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
US20090117105A1 (en) | 2007-11-01 | 2009-05-07 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence | Humanized anti-venezuelan equine encephalitis virus recombinant antibody |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
JP2009181819A (ja) | 2008-01-31 | 2009-08-13 | Hitachi High-Technologies Corp | 荷電粒子線装置 |
JP4438875B2 (ja) | 2008-02-27 | 2010-03-24 | 三菱自動車工業株式会社 | 車両の貯蔵燃料量推定装置 |
EP2132228B1 (en) | 2008-04-11 | 2011-06-22 | Emergent Product Development Seattle, LLC | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
KR20110047255A (ko) | 2008-09-26 | 2011-05-06 | 로슈 글리카트 아게 | 이중특이적 항-egfr/항-igf-1r 항체 |
US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
WO2010065882A1 (en) | 2008-12-04 | 2010-06-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
WO2010112194A1 (en) | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
MX2011010166A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
AU2010233993A1 (en) * | 2009-04-07 | 2011-09-08 | Roche Glycart Ag | Bispecific anti-ErbB-1/anti-c-Met antibodies |
CA2761233A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
PT2483310E (pt) * | 2009-09-29 | 2014-10-07 | Roche Glycart Ag | Anticorpos bi-específicos agonistas do receptor de morte |
JP6048972B2 (ja) | 2010-04-23 | 2016-12-21 | ジェネンテック, インコーポレイテッド | ヘテロ多量体タンパク質の産生 |
RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
WO2012116926A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
MX342034B (es) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
US20130060011A1 (en) | 2011-08-23 | 2013-03-07 | Peter Bruenker | Fc-free antibodies comprising two fab fragments and methods of use |
RS57744B1 (sr) | 2011-08-23 | 2018-12-31 | Roche Glycart Ag | Bispecifični antigen vezujući molekuli |
LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
CA2861124A1 (en) | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
KR20150013188A (ko) | 2012-05-24 | 2015-02-04 | 에프. 호프만-라 로슈 아게 | 다중특이적 항체 |
-
2010
- 2010-03-30 BR BRPI1014089A patent/BRPI1014089A2/pt not_active Application Discontinuation
- 2010-03-30 CA CA 2756244 patent/CA2756244A1/en not_active Abandoned
- 2010-03-30 CN CN201080015592.4A patent/CN102369215B/zh active Active
- 2010-03-30 AU AU2010230563A patent/AU2010230563A1/en not_active Abandoned
- 2010-03-30 PE PE2011001688A patent/PE20120591A1/es not_active Application Discontinuation
- 2010-03-30 MX MX2011010159A patent/MX2011010159A/es active IP Right Grant
- 2010-03-30 RU RU2011143905/10A patent/RU2598248C2/ru not_active IP Right Cessation
- 2010-03-30 KR KR1020117025868A patent/KR101431318B1/ko not_active IP Right Cessation
- 2010-03-30 WO PCT/EP2010/002004 patent/WO2010112193A1/en active Application Filing
- 2010-03-30 EP EP10711847.3A patent/EP2414391B1/en active Active
- 2010-03-30 SG SG2011071479A patent/SG175004A1/en unknown
- 2010-03-30 JP JP2012502505A patent/JP5501439B2/ja active Active
- 2010-03-31 US US12/750,748 patent/US9382323B2/en active Active
- 2010-03-31 AR ARP100101064 patent/AR076018A1/es unknown
- 2010-04-01 TW TW99110151A patent/TW201040265A/zh unknown
-
2011
- 2011-08-18 IL IL214756A patent/IL214756A0/en unknown
- 2011-09-12 ZA ZA2011/06666A patent/ZA201106666B/en unknown
- 2011-09-27 CL CL2011002380A patent/CL2011002380A1/es unknown
-
2012
- 2012-08-28 HK HK12108390.5A patent/HK1167669A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20110130525A (ko) | 2011-12-05 |
JP5501439B2 (ja) | 2014-05-21 |
RU2011143905A (ru) | 2013-05-10 |
AU2010230563A1 (en) | 2011-09-22 |
CL2011002380A1 (es) | 2012-06-15 |
CN102369215B (zh) | 2015-01-21 |
EP2414391B1 (en) | 2018-11-28 |
SG175004A1 (en) | 2011-11-28 |
AR076018A1 (es) | 2011-05-11 |
EP2414391A1 (en) | 2012-02-08 |
CA2756244A1 (en) | 2010-10-07 |
KR101431318B1 (ko) | 2014-08-20 |
WO2010112193A1 (en) | 2010-10-07 |
JP2012522493A (ja) | 2012-09-27 |
HK1167669A1 (en) | 2012-12-07 |
MX2011010159A (es) | 2011-10-17 |
US20100256338A1 (en) | 2010-10-07 |
IL214756A0 (en) | 2011-11-30 |
PE20120591A1 (es) | 2012-05-23 |
US9382323B2 (en) | 2016-07-05 |
CN102369215A (zh) | 2012-03-07 |
ZA201106666B (en) | 2012-05-30 |
TW201040265A (en) | 2010-11-16 |
RU2598248C2 (ru) | 2016-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1014089A2 (pt) | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples | |
BRPI1009547A2 (pt) | animações em cadeia | |
SMT201700083B (it) | Anticorpi monoclonali | |
BRPI0811561A2 (pt) | Dispositivo de iluminação e método de iluminação | |
BRPI1013317A2 (pt) | método de cimentação | |
BR112012004707A2 (pt) | método | |
BR112012011910A2 (pt) | dispositivo e método | |
BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
FI20090389A0 (fi) | Menetelmä | |
DK3091034T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
DK2344537T3 (da) | Bispecifikke anti-vegf/anti-ang-2-antistoffer | |
BRPI0822447A2 (pt) | Anticorpo monoclonal e método do mesmo | |
BRPI0818048A2 (pt) | Dispositivo de iluminação e método de fabricação | |
BR112013005403A2 (pt) | dsispositivo de iluminação baseado e, led, aparelho e método. | |
DK3514173T3 (da) | DKK-1-antistoffer | |
BRPI1012526A2 (pt) | método | |
BRPI1010705A2 (pt) | método | |
DE102011001868A8 (de) | Dichtkette | |
BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
BRPI1012532A2 (pt) | método | |
BRPI0912769A2 (pt) | anticorpos anti-pirb | |
BR112012029474A2 (pt) | método de inspeção de matriz | |
BRPI1009350A2 (pt) | método | |
DE112010000124A5 (de) | Verfahren, betriebsgerät und beleuchtungssystem | |
BRPI1010215A2 (pt) | dispositivo e método |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2467 DE 17/04/2018 POR TER SIDO INDEVIDA. |
|
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |